InvestSMART

Racura Oncology Ltd (ASX: RAC) - Announcements

Current share price for RAC : $1.475 0.005 (0.34%)+

ASX company news and announcements for Racura Oncology Ltd (RAC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Racura Oncology Ltd (RAC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Racura Oncology Ltd (RAC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Racura Oncology Ltd (RAC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$289 Race Joint Venture with TargImmune 10 Jul 2017 9:52AM $0.230 $1.475 risen by 541.30%
$289 Updated Trading Policy 7 Jul 2017 6:08PM n/a $1.475 n/a
$289 Trading Halt 7 Jul 2017 9:43AM $0.230 $1.475 risen by 541.30%
$289 Race Announces NCI Collaboration 4 Jul 2017 11:03AM $0.225 $1.475 risen by 555.56%
$289 Appendix 3Y-Bill Garner 12 May 2017 3:16PM $0.230 $1.475 risen by 541.30%
$289 Appendix 3B 8 May 2017 4:49PM $0.210 $1.475 risen by 602.38%
$289 Appendix 4C - quarterly 19 Apr 2017 5:05PM $0.215 $1.475 risen by 586.05%
$289 Appendix 3Y-Peter Molloy 31 Mar 2017 1:34PM $0.210 $1.475 risen by 602.38%
$289 Replacement Appendix 3Y-Chris Ntoumenopoulos 29 Mar 2017 10:56AM $0.200 $1.475 risen by 637.50%
$289 Appendix 3Y-Chris Ntoumenopoulos 29 Mar 2017 10:23AM $0.205 $1.475 risen by 619.51%
$289 Appendix 3B 28 Mar 2017 7:49PM $0.205 $1.475 risen by 619.51%
$289 Appendix 3Y-Bill Garner 28 Mar 2017 4:50PM $0.205 $1.475 risen by 619.51%
$289 Bisantrene License Agreement for Korea 27 Mar 2017 9:41AM $0.170 $1.475 risen by 767.65%
$289 Race Presents at AusBiotech Global Investment Series 23 Mar 2017 9:40AM $0.170 $1.475 risen by 767.65%
$289 Investor Conference Call Recording 17 Mar 2017 9:28AM $0.195 $1.475 risen by 656.41%
$289 Race Oncology Investor Conference Call 10 Mar 2017 9:39AM $0.195 $1.475 risen by 656.41%
$289 Investor Presentation 9 Mar 2017 9:47AM $0.180 $1.475 risen by 719.44%
$289 Notice Under Section 708A 8 Mar 2017 6:15PM $0.180 $1.475 risen by 719.44%
$289 Appendix 3B 8 Mar 2017 6:15PM $0.180 $1.475 risen by 719.44%
$289 Appendix 4D & Half-Year Financial Statements 24 Feb 2017 7:44PM $0.205 $1.475 risen by 619.51%
$289 Pre-IND Meeting Confirms 505(b)(2) Pathway for Bisantrene 16 Feb 2017 9:48AM $0.195 $1.475 risen by 656.41%
$289 Trading Halt 15 Feb 2017 9:42AM $0.195 $1.475 risen by 656.41%
$289 Appendix 4C - quarterly 20 Jan 2017 7:19PM $0.195 $1.475 risen by 656.41%
$289 Race Oncology Update & Investor Presentation 11 Jan 2017 8:35AM $0.210 $1.475 risen by 602.38%
$289 Prof Martin Tallman joins Race scientific advisory team 12 Dec 2016 9:31AM $0.210 $1.475 risen by 602.38%

926 - 950 of 1002 results

Page 38 of 41

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.